Which company is larger?

Alexandria Real Estate Equities is vastly larger than Global Medical REIT, with a premier portfolio of life science campuses in top innovation markets compared to Global Medical REIT's smaller medical office portfolio.

Why has life science real estate faced challenges recently?

Several major life science markets saw a wave of new lab space construction in recent years, creating a temporary oversupply that has pressured occupancy and rent growth, even for premier operators like Alexandria.

Which offers more growth potential from its current size?

Global Medical REIT's much smaller scale theoretically provides more room for percentage-based growth from acquisitions, though it also carries more concentration and leverage risk than the larger, more diversified Alexandria.

brimindinvest.com / compare / gmre-vs-areLIVE

GMRE

Global Medical REIT Inc. · Real Estate - Healthcare REIT

N/A

N/A this month

VERSUS

⟷

COMPARE

ARE

Alexandria Real Estate Equities, Inc. · Real Estate - Life Science REIT

$51.03

+11.32% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

GMRE

0

ARE

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

GMRE N/A

ARE 25.2

1Y Return

GMRE N/A

ARE -28.35%

Fwd P/E

GMRE N/A

ARE -60.42

Target Up.

GMRE N/A

ARE -3.14%

Op. Margin

GMRE N/A

ARE 15.89%

Metrics last refreshed: 6/20/2026

Quick take

GMRE vs ARE Stock Comparison: AI Score, Valuation, Performance and Upside

ARE is the dominant, large-scale leader in life science real estate with premier lab campuses in top innovation hubs, while GMRE is a much smaller, niche medical office REIT with a more modest growth profile. The comparison highlights very different scales and sub-sectors within healthcare-adjacent real estate.

GMRE vs ARE contrasts a small-cap medical office REIT against the dominant, large-scale leader in life science laboratory real estate.

Live analysis · updated 6/20/2026

GMRE and ARE are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

GMRE

ARE

Not enough data to chart yet.

Recent returns

GMRE

ARE

Analyst price targets & sentiment

GMRE

Price target data unavailable

N/A

ARE

Price target range

analyst mean$51.50
current price$51.03

-3.1% upside to analyst mean

Who should consider this stock?

GMRE may suit investors who:

→Want exposure to smaller-scale, niche medical office real estate
→See value in Global Medical REIT's growth potential from a smaller base
→Are comfortable with higher relative leverage and tenant concentration risk

ARE may suit investors who:

→Want exposure to the dominant leader in life science laboratory real estate
→Value Alexandria's premier locations in top biotech innovation clusters
→Believe life science real estate demand will recover from near-term oversupply pressures

Performance & AI score

Metric	GMRE	ARE
AI score	N/A	25.2
AI rank	N/A	#2835
Latest close	N/A	$51.03
1M return	N/A	+11.32%
6M return	N/A	+7.30%
1Y return	N/A	-28.35%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	GMRE	ARE
1Y ago	N/A	$7.2K (-28.0%) started 2025-06-18
5Y ago	N/A	$3.74K (-62.6%) started 2021-06-21
10Y ago	N/A	$9.8K (-2.0%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	GMRE	ARE
Market cap	N/A	$9.27B
Trailing P/E	N/A	102.99
Forward P/E	N/A	-60.42
Price/Sales	3.30	N/A
EV/Revenue	N/A	8.65
Analyst target	N/A	$51.50
Target upside	N/A	-3.14%

Growth, profitability & risk

Metric	GMRE	ARE
Revenue growth	N/A	-11.50%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	N/A	+48.08%
Operating margin	N/A	15.89%
Profit margin	N/A	-36.14%
ROIC proxy	N/A	-4.14%
Return on equity	N/A	-4.14%
Dividend yield	N/A	5.42%
Beta	0.25	1.20
Debt/equity	N/A	66.51
Current ratio	N/A	0.80
Quick ratio	N/A	0.66

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

GMRE max drawdownN/A

ARE max drawdown53.79%

GMRE max wkly dropN/A

ARE max wkly drop28.48%

5Y risk snapshot

GMRE max drawdownN/A

ARE max drawdown79.30%

GMRE max wkly dropN/A

ARE max wkly drop28.48%

10Y risk snapshot

GMRE max drawdownN/A

ARE max drawdown79.30%

GMRE max wkly dropN/A

ARE max wkly drop28.48%

Performance metrics by period

Period	Metric	GMRE	ARE
1Y	Growth	N/A	-28.01%
	CAGR	N/A	-28.04%
	Sharpe ratio	N/A	-0.61
	Max drawdown	N/A	53.79%
	Max daily drop	N/A	19.17%
	Max wkly drop	N/A	28.48%
5Y	Growth	N/A	-68.17%
	CAGR	N/A	-20.49%
	Sharpe ratio	N/A	-0.66
	Max drawdown	N/A	79.30%
	Max daily drop	N/A	19.17%
	Max wkly drop	N/A	28.48%
10Y	Growth	N/A	-30.09%
	CAGR	N/A	-3.52%
	Sharpe ratio	N/A	-0.13
	Max drawdown	N/A	79.30%
	Max daily drop	N/A	19.17%
	Max wkly drop	N/A	28.48%

Business comparison

Category	GMRE	ARE
Company	Global Medical REIT Inc.	Alexandria Real Estate Equities, Inc.
Sector	Real Estate - Healthcare REIT	Real Estate
Industry	N/A	N/A
Core business	Global Medical REIT is a smaller healthcare REIT that owns medical office buildings and other healthcare-related real estate, leasing properties to physician groups and healthcare systems under long-term net leases.	Alexandria Real Estate Equities is the leading life science real estate REIT, developing and owning lab and office campuses clustered in major life science innovation hubs like Boston, San Francisco, and San Diego.
Investor focus	Investors track Global Medical REIT's acquisition pace and cap rates, tenant credit quality, and dividend coverage given its smaller scale relative to larger healthcare REIT peers.	Investors track Alexandria's life science lab leasing demand, development pipeline progress, and occupancy trends amid a period of elevated new life science supply in some markets.

GMRE strengths

→Focused, niche strategy targeting outpatient medical office properties
→Smaller scale provides more room for percentage-based portfolio growth
→Net lease structure with healthcare tenants provides relatively stable, predictable cash flow

ARE strengths

→Dominant position in premier life science real estate clusters with high barriers to entry
→Strong, long-standing relationships with leading biotech and pharmaceutical tenants
→Large, well-located development pipeline supports long-term growth

Risks to watch — GMRE

→Much smaller scale than larger healthcare REIT peers limits capital cost and diversification advantages
→Higher relative leverage and tighter dividend coverage than larger, better-capitalized peers
→Tenant concentration risk given smaller overall portfolio size

Risks to watch — ARE

→Life science real estate has faced near-term oversupply pressure in some major markets
→Biotech tenant funding environment directly affects lab space demand
→Larger scale and higher valuation require sustained execution to justify

Frequently asked questions

Medical office buildings, Global Medical REIT's focus, house outpatient physician practices and clinical services, while life science real estate, Alexandria's focus, consists of specialized laboratory and research space for biotech and pharmaceutical companies.

AI Prediction SignalNext 5 trading days

Members only

GMRE

+2.8%BUY

ARE

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons

ARE vs EQIX

Life Sciences REIT vs Data Center REIT